Drug Profile
Research programme: autologous gene therapy - Orchard Therapeutics
Alternative Names: Ex-vivo lentiviral gene therapy - Orchard TherapeuticsLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Central Manchester University Hospitals NHS Foundation Trust; University of Manchester
- Developer Orchard Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders; Metabolic disorders
Most Recent Events
- 24 Jan 2024 Orchard Therapeutics has been acquired by Kyowa Kirin
- 22 Sep 2023 Preclinical development is ongoing in Immunological-disorders in United Kingdom (Parenteral) (Orchard Therapeutics website; September 2023).
- 28 May 2018 No recent reports of development identified for preclinical development in Immunological-disorders in United Kingdom (Parenteral)